• Cancer Immunology and AIDS

    The department performs basic research in cancer immunology and virology and develops new therapeutic strategies based on novel mechanistic insights. Cancer immunology is now one of the most exciting and important areas of investigation in the cancer field. Recent clinical trials …

    read more ›  
     
     

    The magnitude and durability of responses to immunotherapies in patients with diverse types of cancer are unprecedented in oncology. Dana-Farber has a long history of excellence in this field, and our immunology investigators have made important contributions to these
    advances …

    read more ›  
     
     

    Cancer immunology is an important part of the fabric of the Institute, and our mission is to serve as an intellectual center for cancer immunology efforts across the Institute and the Harvard Medical School community. Many investigators from other fields …

    read more ›  
     
     

    We closely collaborate with our clinical colleagues, aiming for a seamless transition from basic discovery to clinical translation. This sense of community is fostered at monthly faculty meetings in which all investigators interested in immunology are invited to participate, including …

    read more ›  
     
     

    We emphasize development and implementation of cutting-edge technologies that enhance our ability to study immune responses in animal models and patients. An example is the mass cytometry technology (CyTOF) which enables simultaneous analysis of >30 intracellular and cell surface molecules …

    read more ›  
     
     
     
  • Research Focus

    • Basic immunological mechanisms

      All therapeutic advances in cancer immunology are based on our growing understanding of fundamental immunological mechanisms. We approach immunology as a complex system in which many cell populations activate and regulate each other. We believe that the complexity of the … read more ›  

    • Cancer immunology and immunotherapy

      Our department is developing novel approaches for immunotherapy, and we closely collaborate with our clinical colleagues to advance important discoveries to clinical trials. The Wucherpfennig Lab has developed a novel approach for systematic discovery of negative regulators of T cell function … read more ›  

    • Viral immunology

      HIV infects a critical population of immune cells (CD4 T cells), resulting in an immunodeficiency syndrome that predisposes to opportunistic infections and cancer. A shared interest by HIV and cancer immunology investigators is the development of vaccines that stimulate strong … read more ›  

    • Cancer Immunology Working Group

      At monthly faculty meetings, basic and clinical immunologists discuss ongoing research in their labs in order to foster translation of immunological principles into clinical immunotherapy trials. Immunologists in other departments are part of our vibrant immunology community and contribute expertise … read more ›  

    Related Links

    Highlights

    Wayne Marasco

    MAY 2014

    Dana-Farber researcher blocks MERS virus in experiment 

    For two years, Dana-Farber researchers have been studying the MERS virus, and they recently discovered a way to combat the deadly pathogen by blocking its ability to enter and infect cells. Wayne Marasco, MD, PhD, has identified a molecule … full story 

    Michael Goldberg

    MAR 2014

    Turning back the clock on cancer 

    Preventing cancer, or even reversing its earliest stages, would be hugely preferable to treating more advanced cases. Now, Dana-Farber researcher Michael Goldberg, PhD, has contributed to research that demonstrates one way this might work. “Conventional wisdom holds that we must … full story 

    JAN 2014

    In vivo discovery of targets for cancer immunotherapy 

    Therapeutic targets are typically identified using in vitro approaches, but the complex interactions of migratory immune cells with many other cell populations are very difficult to model using in vitro systems. The Wucherpfennig lab developed an in vivo shRNA screening … full story